Despite its enormous global burden, osteoarthritis has no licensed disease-modifying treatments, and available analgesics have moderate efficacy and substantial side-effects.1 The success of ...
In 2023, researchers at Baylor College of Medicine led by the late Dr. Bert O'Malley discovered that the steroid receptor ...
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
CHICAGO -- Classifying inflammatory subphenotypes of acute respiratory distress syndrome (ARDS) with bedside lab testing was ...
8h
CD Bioparticles Launches Extrahepatic RNA Delivery Services to to Advance Nucleic Acid Therapeutics
CD Bioparticles announces the launch of comprehensive Extrahepatic RNA Delivery services. NEW YORK, NY, UNITED STATES, ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Not all drug users are the same. To understand different profiles of patients that use addictive substances, research frameworks typically classify cases by ...
Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) ...
Researcher at Harvard Medical School develops AI-driven molecule targeting tumor mitochondria defects to destroy cancer ...
DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...
The FDA has approved relacorilant (Lifyorli, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal ...
Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature, of collaborative studies with Duke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results